Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Millicent MacGregor, RN
- Phone Number: 317-274-5288
- Email: milmacgr@iu.edu
Study Contact Backup
- Name: John Spittler, RN
- Phone Number: (317) 274-0771
- Email: ajspittl@iu.edu
Study Locations
-
-
Indiana
-
Carmel, Indiana, United States, 46032
- IU Health Joe and Shelly Schwarz Cancer Center
-
Indianapolis, Indiana, United States, 46202
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Ability to provide written informed consent and HIPAA authorization
- Patients deemed eligible and willing to receive a COVID-19 vaccine by treating physician per standard of care.
- Subjects must be ≥ 18 years old at the time of consent.
Diagnosis of cancer and fall into one of the groups below:
- Group 1: Patients with solid tumors receiving courses of cytotoxic therapy.
- Group 2: Patients with hematological cancers receiving courses of cytotoxic chemotherapy.
- Group 3: Patients with solid tumors receiving tyrosine kinase inhibitors (TKIs) or other targeted therapies, but not cytotoxic regimens within 3 months.
- Group 4: Patients with hematologic cancers receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months.
- Group 5: Patients receiving immune checkpoint inhibitors.
- Group 6: Patients who underwent allogeneic stem cell transplant within 12 months.
- Group 7: Patients who underwent cellular therapy, including Chimeric antigen receptor t-cells (CAR-T) cells or t-cells with engineered t-cell receptors (TCRs) within 12 months.
- Group 8: Patients in remission who have received cellular therapy more than 12 months in the past, including allogeneic, autologous or engineered cellular approaches.
- Group 9: Patients with cancer in remission for at least 2 years not receiving active cytotoxic cancer chemotherapy (hormonal therapy is permitted).
- Group 10: Patients who have undergone allogenic bone marrow transplant and are currently receiving immunosuppressants
- Group 11: Patients who have undergone allogenic bone marrow transplant who are not currently receiving immunosuppressants
- Group 12: Patients who have a cancer diagnosis but do not fall into group 1-11
3. Estimated survival of 8 weeks or more following enrollment on the study.
Exclusion Criteria:
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active COVID-19 infection or influenza-like-illness. If subjects have previously tested positive for COVID-19 infection, they are eligible to participate in this study after 90 days
- Unwilling or unable to follow protocol requirements.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group 1
Patients with solid tumors receiving courses of cytotoxic therapy.
|
Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Other Names:
|
|
Group 2
Patients with hematological cancers receiving courses of cytotoxic chemotherapy.
|
Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Other Names:
|
|
Group 3
Patients with solid tumors receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months
|
Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Other Names:
|
|
Group 4
Patients with hematologic cancers receiving TKIs or other targeted therapies, but not cytotoxic regimens within 3 months
|
Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Other Names:
|
|
Group 5
Patients receiving immune checkpoint inhibitors.
|
Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Other Names:
|
|
Group 6
Patients who underwent allogeneic stem cell transplant within 12 months.
|
Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Other Names:
|
|
Group 7
Patients who underwent cellular therapy, including CAR-T cells or T cells with engineered TCRs within 12 months.
|
Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Other Names:
|
|
Group 8
Patients in remission who have received cellular therapy more than 12 months in the past, including allogeneic, autologous or engineered cellular approaches
|
Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Other Names:
|
|
Group 9
Patients with cancer in remission for at least 2 years not receiving active cytotoxic cancer chemotherapy (hormonal therapy is permitted).
|
Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Other Names:
|
|
Group 10
Patients who have undergone allogenic bone marrow transplant and are currently receiving immunosuppressants
|
Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Other Names:
|
|
Group 11
Patients who have undergone allogenic bone marrow transplant who are not currently receiving immunosuppressants
|
Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Other Names:
|
|
Group 12
Patients who have a cancer diagnosis but do not fall into group 1-11
|
Subjects will receive either the Moderna (mRNA-1273), Pfizer (BTN162b2), or Janssen (Ad26.COV2.S) vaccination per standard of care
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse Event Collection
Time Frame: from date of vaccination until 2 months after full vaccination
|
from date of vaccination until 2 months after full vaccination
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of COVID-19 infection
Time Frame: from date of vaccination until 6 months after full vaccination
|
from date of vaccination until 6 months after full vaccination
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Utpal Dave, MD, Indiana University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CTO-IUSCCC-0759
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.